Role of histone acetylation in cell physiology and diseases: An update

Clinica Chimica Acta

Volumn 411, Issue 19-20, 2010, Pages 1401-1411

  Khan, Shahper N ^a   Khan, Asad U ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Cell physiology; Diseases; Epigenetics; Histone acetylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DEXAMETHASONE; FRAGILE X MENTAL RETARDATION PROTEIN; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR E2F; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DEVELOPMENT; ENZYME SPECIFICITY; EPIGENETICS; EPILEPSY; EUCHROMATIN; FRAGILE X SYNDROME; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ACETYLATION; ANIMALS; CELL PHYSIOLOGICAL PHENOMENA; DISEASE; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS;

EUKARYOTA;

EID: 77955051048     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.020     Document Type: Review

References (164)

1. Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R., et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Revs 2005, 25:261-309.
2. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
3. Luger K., Mäder A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8A resolution. Nature 1997, 389:251-260.
4. Parseghian M.H., Newcomb R.L., Winokur S.T., Hamkalo B.A. The distribution of somatic H1 subtypes is non-random on active vs. inactive chromatin: distribution in human fetal fibroblasts. Chromosome Res 2000, 8:405-424.
5. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
6. Berger S.L. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002, 12:142-148.
7. Turner B.M. Cellular memory and the histone code. Cell 2002, 111:285-291.
8. Fischle W., Wang Y., Allis C.D. Binary switches and modification cassettes in histone biology and beyond. Nature 2003, 425:475-479.
9. Brownell J.E., Zhou J., Ranalli T., Kobayashi R., Edmondson D.G., Roth S.Y., et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996, 84:843-851.
10. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc Natl Acad Sci USA 1964, 51:786-794.
11. Khan A.U., Krishnamurthy S. Histone modifications as key regulators of transcription. Front Biosci 2005, 10:866-872.
12. Khan A.U., Hampsey M. Connecting the DOTs: covalent histone modifications and the formation of silent chromatin. Trends Genet 2002, 18:387-389.
13. Kurdistani S.K., Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003, 4(4):276-284.
14. Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98:285-294.
15. Yang X.J. Lysine acetylation and bromodomain: a new partnership for signaling. Bioessays 2004, 26:1076-1087.
16. Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399:491-496.
17. Hassan A.H., Prochasson P., Neely K.E., Galasinski S.C., Chandy M., Carrozza M.J., et al. Function and selectivity of bromodomains in anchoring chromatin modifying complexes to promoter nucleosomes. Cell 2002, 111:369-379.
18. Mujtaba S., He Y., Zeng L., Yan S., Plotnikova O. Sachchidanand Sanchez R, Zeleznik-Le NJ, Ronai Z and Zhou MM. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004, 13:251-263.
19. Jacobson R.H., Ladurner A.G., King D.S., Tjian R. Structure and function of a human TAFII250 double bromodomain module. Science 2000, 288:1422-1425.
20. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998, 12:599-606.
21. Vogelauer M., Wu J., Suka N., Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408:495-498.
22. Kurdistani S.K., Tavazoie S., Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell 2004, 117:721-733.
23. Dion M.F., Altschuler S.J., Wu L.F., Rando O.J. Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci USA 2005, 102:5501-5506.
24. Pokholok D.K., Harbison C.T., Levine S., Cole M., Hannett N.M., Lee T.I., et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 2005, 122:517-527.
25. Schubeler D., Turner B.M. A new map for navigating the yeast epigenome. Cell 2005, 122:489-492.
26. Fischle W., Wang Y., Allis C.D. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003, 15:172-183.
27. Davie J.R. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev 1998, 8:173-178.
28. Verdone L., Caserta M., Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005, 83:344-353.
29. Waterborg J.H. Dynamics of histone acetylation in Saccharomyces cerevisiae. Biochemistry 2001, 40:2599-2605.
30. Katan-Khaykovich Y., Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 2002, 16:743-752.
31. Deckert J., Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell 2001, 21:2726-2735.
32. Hebbes T.R., Clayton A.L., Thorne A.W., Crane-Robinson C. Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken beta-globin chromosomal domain. EMBO J 1994, 13:1823-1830.
33. Vettese-Dadey M., Grant P.A., Hebbes T.R., Crane-Robinson C., Allis C.D., Workman J.L. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J 1996, 15:2508-2518.
34. Durrin L.K., Mann R.K., Kayne P.S., Grunstein M. Yeast histone H4 N-terminal sequence is required for promoter activation in vivo. Cell 1991, 65:1023-1031.
35. Yoshida M., Horinouchi S., Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995, 17:423-430.
36. Schübeler D., Francastel C., Cimbora D.M., Reik A., Martin D.I., Groudine M. Nuclear localization and histone acetylation: a pathway for chromatin opening and transcriptional activation of the human β-globin locus. Genes Dev 2000, 14:940-950.
37. Forsberg E.C., Bresnick E.H. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 2001, 23:820-830.
38. Imhof A., Becker P.B. Modifications of the histone N-terminal domains. Evidence for an "epigenetic code"?. Mol Biotechnol 2001, 17:1-13.
39. Gu W., Roeder R.G. Activation of p53 sequence specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
40. Kuo M.H., Zhou J., Jambeck P., Churchill M.E., Allis C.D. Histone acetyltransferase activity of yeast Gcn5p is required for the activation of target genes in vivo. Genes Dev 1998, 12:627-639.
41. Rundlett S.E., Carmen A.A., Kobayashi R., Bavykin S. Turner BM and Grunstein M HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes. Proc Natl Acad Sci 1996, 93:14503-14508.
42. Kadosh D., Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997, 89:365-371.
43. Timmermann S., Lehrmann H., Polesskaya A., Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001, 58:728-736.
44. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell 1992, 71:875-886.
45. Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S., et al. The translocation t(8;l6)(p11, p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996, 14:33-41.
46. Carapeti M., Aguiar R.C., Watmore A.E., Goldman J.M., Cross N.C. Consistent fusion of MOZ and TIF2 in AML with inv (8) (p11q13). Cancer Genet Cytogenet 1999, 113:70-72.
47. Hilfiker A., Hilfiker-Kleiner D., Pannuti A., Lucchesi J.C. mof a putative acetyl transferase gene related to the TIP60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J 1997, 16:2054-2060.
48. Carrozza M.J., Utley R.T., Workman J.L., Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003, 19:321-329.
49. Creaven M., Hans F., Mutskov V., Col E., Caron C., Dimitrov S., et al. Control of the histone acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat. Biochemistry 1999, 38:8826-8830.
50. Brady M.E., Ozanne D.M., Gaughan L., Waite I., Cook S., Neal D.E., et al. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 1999, 274(25):17599-17604.
51. Mizzen C.A., Yang X.J., Kokubo T., Brownell J.E., Bannister A.J., Owen-Hughes T., et al. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 1996, 87:1261-1270.
52. Wang E.H., Tjian R. Promoter-selective transcriptional defect in cell cycle mutant ts13 rescued by hTAFII250. Science 1994, 263:811-814.
53. Park S.J., Kim M., Kim N.H., Oh M.K., Cho J.K., Jin J.Y., et al. Auranofin promotes retinoic acid- or dihydroxyvitamin D(3)-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br J Pharmacol 2008, 154:1196-1205.
54. Golob J.L., Paige S.L., Muskheli V., Pabon L., Murry C.E. Chromatin remodeling during mouse and human embryonic stem cell differentiation. Dev Dyn 2008, 237:1389-1398.
55. Chen G., Zhu J., Lv T., Wu G., Sun H., Huang X., et al. Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts. J Biomed Sci 2009, 16:24-34.
56. Creppe C., Malinouskaya L., Volvert M.L., Gillard M., Close P., Malaise O., et al. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell 2009, 136:551-564.
57. Zhong X., Jin Y. Critical roles of coactivator p300 in mouse embryonic stem cell differentiation and Nanog expression. J Biol Chem 2009, 284:9168-9175.
58. Shang Y., Yoshida T., Amendt B.A., Martin J.F., Owens G.K. Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J Cell Biol 2008, 181:461-473.
59. Bhaumik S.R., Smith E., Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007, 14:1008-1016.
60. Gomez R.A., Pentz E.S., Jin X., Sequeira Lopez M.L. CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. Am J Physiol Heart Circ Physiol 2009, 296:H1255-H1262.
61. Guelman S., Kozuka K., Mao Y., Pham V., Solloway M.J., Wang J., et al. The double-histone-acetyltransferase complex ATAC is essential for mammalian development. Mol Cell Biol 2009, 29:1176-1188.
62. Lin W., Dent S.Y. Functions of histone-modifying enzymes in development. Curr Opin Genet Dev 2006, 16:137-142.
63. Brinkman A.B., Roelofsen T., Pennings S.W., Martens J.H., Jenuwein T., Stunnenberg H.G. Histone modification patterns associated with the human X chromosome. EMBO Rep 2006, 7:628-634.
64. Leal C.A., Ayala-Madrigal M.L., Figuera L.E., Medina C. Histone H4 acetylation analyses in patients with polysomy X: implications for the mechanism of X inactivation. Hum Genet 1998, 103:29-33.
65. Thomas T., Dixon M.P., Kueh A.J., Voss A.K. Mof (MYST1 or KAT8) is essential for progression of embryonic development past the blastocyst stage and required for normal chromatin architecture. Mol Cell Biol 2008, 28:5093-5105.
66. Rowland B.D., Roig M.B., Nishino T., Kurze A., Uluocak P., Mishra A., et al. Building sister chromatid cohesion: smc3 acetylation counteracts an antiestablishment activity. Mol Cell 2009, 33:763-774.
67. Keenen B., de la Serna I.L. Chromatin remodeling in embryonic stem cells: regulating the balance between pluripotency and differentiation. J Cell Physiol 2009, 219:1-7.
68. Gu W., Roeder R.G. Activation of p53 sequence specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
69. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000, 19:662-671.
70. Sartorelli V., Puri P.L., Hamamori Y., Ogryzko V., Chung G., Nakatani Y., et al. Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. Mol Cell 1999, 4:725-734.
71. Cho Y., Song S.H., Lee J.J., Choi N., Kim C.G., Dean A., et al. The role of transcriptional activator GATA-1 at human beta-globin HS2. Nucleic Acids Res 2008, 36:4521-4528.
72. Roelfsema J.H., Peters D.J. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 2007, 9:1-16.
73. Bundy J.G., Iyer N.G., Gentile M.S., Hu D.E., Kettunen M., Maia A.T., et al. Metabolic consequences of p300 gene deletion in human colon cancer cells. Cancer Res 2006, 66:7606-7614.
74. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303.
75. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001, 268:2773-2778.
76. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999, 19:1202-1209.
77. Sears R., Ohtani K., Nevins J.R. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 1997, 17:5227-5235.
78. Gray S.G., Ekstrom T.J. The human histone deacetylse family. Exp Cell Res 2006, 262(2):75-83.
79. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002, 277:25748-25755.
80. Liu H., Hu Q., Kaufman A., D'Ercole A.J., Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J Neurosci Res 2008, 86:537-543.
81. Schwer B., Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 2008, 7:104-112.
82. Longo V.D., Kennedy B.K. Sirtuins in aging and age-related disease. Cell 2006, 126:257-268.
83. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868-874.
84. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008, 30:61-72.
85. Montgomery R.L., Potthoff M.J., Haberland M., Qi X., Matsuzaki S., Humphries K.M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008, 118:3588-3597.
86. Song K., Backs J., McAnally J., Qi X., Gerard R.D., Richardson J.A., et al. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 2006, 125:453-466.
87. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008, 28:1688-1701.
88. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126:321-334.
89. Kasler H.G., Verdin E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol 2007, 27:5184-5200.
90. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004, 24:8467-8476.
91. Backs J., Song K., Bezprozvannaya S., Chang S., Olson E.N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 2006, 116:1853-1864.
92. Oka S.I., Ago T., Kitazono T., Zablocki D., Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med 2009, 87:785-791.
93. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119:555-566.
94. Bassel-Duby R., Olson E.N. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 2006, 75:19-37.
95. Potthoff M.J., Wu H., Arnold M.A., Shelton J.M., Backs J., McAnally J., et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 2007, 117:2459-2467.
96. Méjat A., Ramond F., Bassel-Duby R., Khochbin S., Olson E.N., Schaeffer L. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 2005, 8:313-321.
97. Kurland J.F., Tansey W.P. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 2008, 68:3624-3629.
98. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
99. Dasgupta P., Sun J., Wang S., Fusaro G., Betts V., Padmanabhan J., et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004, 24(21):9527-9541.
100. Davis R.K., Chellappan S. Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer. Drug News Perspect 2008, 21:331-335.
101. Hahm E.R., Singh S.V. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007, 6:2686-2695.
102. Haberland M., Johnson A., Mokalled M.H., Montgomery R.L., Olson E.N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 2009, 106:7751-7755.
103. Wallace D.M., Cotter T.G. Histone deacetylase activity in conjunction with E2F-1 and p53 regulates Apaf-1 expression in 661W cells and the retina. J Neurosci Res 2009, 87:887-905.
104. Turner B.M., Birley A.J., Lavender J. Histone H4 isoforms acetylated at specific lysine residues define individual chromosomes and chromatin domains in Drosophila polytene nuclei. Cell 1992, 69:375-384.
105. Braunstein M., Sobel R.E., Allis C.D., Turner B.M., Broach J.R. Efficient transcriptional silencing in Saccharomyces cerevisiae requires a heterochromatin histone acetylation pattern. Mol Cell Biol 1996, 16:4349-4356.
106. Kuo M.H., Brownell J.E., Sobel R.E., Ranalli T.A., Cook R.G., Edmonson D.G., et al. Transcription-linked acetylation by GCN5p of histones H3 and H4 at specific lysines. Nature 1996, 383:269-272.
107. Rundlett S.E., Carmen A.A., Kobayashi R., Bavykin S., Turner B.M., Grunstein M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes. Proc Natl Acad Sci 1996, 93:14503-14508.
108. Grant P.A., Duggan L., Cote J., Roberts S.M., Brownell J.E., Candau R., et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complexs. Genes Dev 1997, 11:1640-1650.
109. Rojas J.R., Trievel R.C., Zhou J., Mo Y., Li X., Berger S.L., et al. Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Nature 1999, 401:93-98.
110. Trievel R.C., Rojas J.R., Sterner D.E., Venkataramani R.N., Wang L., Zhou J., et al. Crystal structure and mechanism of histone acetylation of the yeast GCN5 transcriptional coactivator. Proc Natl Acad Sci USA 1999, 96:8931-8936.
111. Clements A., Rojas J.R., Trievel R.C., Wang L., Berger S.L., Marmorstein R. Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A. EMBO J 1999, 18:3521-3532.
112. Yan Y., Barlev N.A., Haley R.H., Berger S.L., Marmorstein R. Crystal structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate binding by histone acetyltransferases. Mol Cell 2000, 6:1195-1205.
113. Dutnall R.N., Tafrov S.T., Sternglanz R., Ramakrishnan V. Structure of the histone acetyltransferase Hat1: a paradigm for the GCN5-related N-acetyltransferase superfamily. Cell 1998, 94:427-438.
114. Clements A., Poux A.N., Lo W.S., Pillus L., Berger S.L., Marmorstein R. Structural basis for histone and phosphohistone binding by the GCN5 histone acetyltransferase. Mol Cell 2003, 12:461-473.
115. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2003, 176:5015-5022.
116. Glauben R., Siegmund B. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer. Meth Mol Biol 2009, 512:365-376.
117. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002, 99:2995-3000.
118. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. Immunol 2006, 176:5015-5022.
119. Cao D., Bromberg P.A., Samet J.M. COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1. Am J Respir Cell Mol Biol 2007, 37:232-239.
120. Su R.C., Becker A.B., Kozyrskyj A.L., Hayglass K.T. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2007, 121:57-63.
121. Hew M., Bhavsar P., Torrego A., Meah S., Khorasani N., Barnes P.J., et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006, 174:134-141.
122. Bergeron C., Fukakusa M., Olivenstein R., Lemiere C., Shannon J., Ernst P., et al. Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma. J Allergy Clin Immunol 2006, 117:703-705.
123. Kelly A., Bowen H., Jee Y.K., Mahfiche N., Soh C., Lee T., et al. The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases. J Allergy Clin Immunol 2007, 121:203-208.
124. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappa B suppression. J Exp Med 2006, 203:7-13.
125. Miao F., Gonzalo I.G., Lanting L., Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic Conditions. J Biol Chem 2004, 279:18091-18097.
126. Guha M., Bai W., Nadler J.L., Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000, 275:17728-17739.
127. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003, 52:1256-1264.
128. Cervantes-Laurean D., Jacobson E.L., Jacobson M.K. Glycation and glycoxidation of histones by ADP-ribose. J Biol Chem 1996, 271:10461-10469.
129. Gugliucci A., Bendayan M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem Biophys Res Commun 1995, 212:56-62.
130. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
131. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817-822.
132. Coffee B., Zhang F., Warren S.T., Reines D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 1999, 22:98-101.
133. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000, 9:2197-2202.
134. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000, 97:6763-6768.
135. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
136. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 2001, 98:15179-15184.
137. Rai M., Soragni E., Jenssen K., Burnett R., Herman D., Coppola G., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoSONE 2008, 3:e1958.
138. Milutinovic S., D'Alessio A.C., Detich N., Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2006, 28:560-571.
139. Lagace D.C., Nachtigal M.W. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004, 279:18851-18860.
140. Weaver I.C., Meaney M.J., Szyf M. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 2006, 103:3480-3485.
141. Weaver I.C., Champagne F.A., Brown S.E., Dymov S., Sharma S., Meaney M.J., et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005, 25:11045-11054.
142. Naahidi S. In vivo epigenetic study of histone acetylation associated with obesity, masters' dissertation 2007, Waterloo, Ontario, Canada.
143. Remacle C., Bieswal F., Reusens B. Programming of obesity and cardiovascular disease. Int J Obes Relat Metab Disord 2004, 28:S46-S53.
144. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 2006, 600:46-57.
145. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
146. Kang J., Chen J., Shi Y., Jia J., Zhang Y. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol 2005, 69:1205-1213.
147. Santos-Rosa H., Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005, 41:2381-2402.
148. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391-400.
149. Kung A.L., Rebel V.I., Bronson R.T., Ch'ng L.E., Sieff C.A., Livingston D.M., et al. Gene dosedependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000, 14:272-277.
150. Shigeno K., Yoshida H., Pan L., Luo J.M., Fujisawa S., Naito K., et al. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett 2004, 213:11-20.
151. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303.
152. Urnov F.D., Yee J., Sachs L., Collingwood T.N., Bauer A., Beug H., et al. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J 2000, 19:4074-4090.
153. Zelent A., Waxman S., Carducci M., Wright J., Zweibel J., Gore S.D. State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003. Clin Cancer Res 2004, 10:4622-4629.
154. Miyamoto K., Ushijima T. Diagnostic and therapeutic applications of epigenitics. Jpn J Clin Oncol 2005, 35:293-301.
155. Gilbert J., Gore S.D., Herman J.G., Carducci M.A. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 2004, 10:4589-4596.
156. Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A., Rosty C., et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003, 63:4158-4166.
157. Bramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/non histone proteins and histone acetyltransferasedependent chromatin transcription. J Biol Chem 2004, 279:51163-51171.
158. Al S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of Ikappa B alpha kinase and Akt activation. Mol Pharmacol 2006, 69:195-206.
159. Stimson L., Rowlands M.G., Newbatt Y.M., Smith N.F., Raynaud F.I., Rogers P., et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005, 4:1521-1532.
160. Yan L., Nass S.J., Smith D., Nelson W.G., Herman J.G., Davidson N.E. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptoralpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2003, 2:552-556.
161. Marks P.A., Miller T., Richon V.M. Histone deacetylases. Curr Opin Pharmacol 2003, 3:344-351.
162. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9:3578-3588.
163. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
164. Xiao H., Hasegawa T., Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999, 73:291-302.